HomeCompareVIDA vs JNJ

VIDA vs JNJ: Dividend Comparison 2026

VIDA yields 20000000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VIDA wins by $1.378983907781291e+33M in total portfolio value
10 years
VIDA
VIDA
● Live price
20000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1.378983907781291e+33M
Annual income
$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00
Full VIDA calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — VIDA vs JNJ

📍 VIDA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVIDAJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VIDA + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
VIDA pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VIDA
Annual income on $10K today (after 15% tax)
$1,700,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$1,160,448,499,073,213,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, VIDA beats the other by $1,160,448,499,073,213,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VIDA + JNJ for your $10,000?

VIDA: 50%JNJ: 50%
100% JNJ50/50100% VIDA
Portfolio after 10yr
$6.894919538906455e+32M
Annual income
$682,616,764,160,713,500,000,000,000,000,000,000,000.00/yr
Blended yield
99.00%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

VIDA
No analyst data
Altman Z
-182.1
Piotroski
3/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VIDA buys
0
JNJ buys
0
No recent congressional trades found for VIDA or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVIDAJNJ
Forward yield20000000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%28%
Portfolio after 10y$1.378983907781291e+33M$30.5K
Annual income after 10y$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$1.3780804039422322e+33M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: VIDA vs JNJ ($10,000, DRIP)

YearVIDA PortfolioVIDA Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$1,000,010,700$1,000,000,000.00$10,594$274.49+$1000.00MVIDA
2$46,730,541,974,066$46,729,471,962,616.81$11,294$360.69+$46730541.96MVIDA
3$1,020,456,630,513,561,600$1,020,406,628,833,649,400.00$12,133$476.91+$1020456630513.55MVIDA
4$10,413,549,150,437,309,000,000$10,412,457,261,842,660,000,000.00$13,156$635.42+$10413549150437308.00MVIDA
5$49,663,934,918,154,680,000,000,000$49,652,792,420,563,720,000,000,000.00$14,432$854.61+$49663934918154682368.00MVIDA
6$110,708,450,458,551,960,000,000,000,000$110,655,310,048,189,540,000,000,000,000.00$16,056$1,162.76+$1.1070845045855196e+23MVIDA
7$115,383,637,844,852,680,000,000,000,000,000$115,265,179,802,862,020,000,000,000,000,000.00$18,175$1,604.53+$1.1538363784485268e+26MVIDA
8$56,260,281,340,608,930,000,000,000,000,000,000$56,136,820,848,114,940,000,000,000,000,000,000.00$21,009$2,252.68+$5.626028134060893e+28MVIDA
9$12,850,821,925,106,690,000,000,000,000,000,000,000$12,790,623,424,072,240,000,000,000,000,000,000,000.00$24,911$3,229.73+$1.285082192510669e+31MVIDA
10$1,378,983,907,781,291,200,000,000,000,000,000,000,000$1,365,233,528,321,427,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$1.378983907781291e+33MVIDA

VIDA vs JNJ: Complete Analysis 2026

VIDAStock

Vidaroo Corporation, a video technology company, engages in licensing an online video platform and performing professional video production activities. It operates and licenses an online video platform under a software-as-a-service model that consists of a series of Web-based applications, a centralized user console, and an application for the management of the platform. The company's video platform is divided into two editions comprising Publisher, which is divided into a series of modules; and Enterprise edition that allows management of multiple content destinations. It licenses its video platform in on-demand and enterprise programs. The company's video platform provides video management, live streaming, content delivery and syndication, player functionality, social destination, analytics, and advertising capabilities. It is also involved in the creation and support of video imagery in the entertainment business; and support of video production for traditional media and corporate presentations, and in-house production of content. The company was formerly known as Gen2Media Corporation and changed its name to Vidaroo Corporation in April 2010. Vidaroo Corporation is based in Winter Garden, Florida.

Full VIDA Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this VIDA vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VIDA vs SCHDVIDA vs JEPIVIDA vs OVIDA vs KOVIDA vs MAINVIDA vs ABBVVIDA vs MRKVIDA vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.